Ademi LLP is investigating Singular Genomics (Nasdaq: OMIC) for possible breaches of fiduciary duty and other violations of law in its transaction with the Deerfield.

Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.

In the transaction, Singular Genomics shareholders will receive $20.00 per share. Singular Genomics insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Singular Genomics by imposing a significant penalty if Singular Genomics accepts a competing bid. We are investigating the conduct of Singular Genomics’ board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241223111268/en/